Samil Pharmaceutical participated in the 'CPHI Japan 2024 Event' held in Tokyo, Japan from the 17th to the 19th.
He participated in the exhibition with executives and employees of the global business team, including Kwon Tae-geun, executive director of Vietnam Plant CMO and CDMO projects.
In addition to Samil Pharmaceutical's Vietnamese eye drops production plant, it introduced various products in the field of eye diseases such as Revakay eye drops and i2uomini eye drops, making all-out efforts to promote companies and attract customers.
Through on-site meetings, we discussed the possibility of various cooperation with leading global companies such as Japan, Europe, China, and Asia, including consignment production through Vietnamese plants.
In particular, major Japanese companies dealing with ophthalmic products such as Senju Pharmaceutical, Rohto Pharmaceutical, Rohto Nitten, Towa Pharmaceutical, Teika Pharmaceutical, and Lion visited the Samil Pharmaceutical Exhibition Hall to explore future shared growth plans among companies.
Samil Pharmaceutical's ophthalmic CMO and CDMO factories located in Ho Chi Minh City, Vietnam, have lines that can produce disposable eye drops, multi-use eye drops, and multi-use non-preservation eye drops.
We are planning to launch our own brand eye drops in North America within this year based on our experience, know-how, and global network in the field of eye diseases, a Samil Pharmaceutical official said. "We are planning to enter the global eye drops market to supply high-quality medicines to the world through full-scale commercial production in 2025 when GMP approval for factories in Vietnam is completed."
[WIKI KOREA=Cho Pil Hyun, Staff Reporter]
chop23@wikileaks-kr.org
